Evidence map›Paper›PMID 42550844›Full record

ArticlePloS one2026

Feasibility of establishing a serosurveillance system using residual specimens from district-level hospitals: A case study in Choma and Ndola Districts of Zambia.

Christine Prosperi, Natalya Kostandova, Andrea C Carcelen, Kalumbu H Matakala, Innocent C Bwalya, Gloria Musukwa, Mutinta Hamahuwa, Irene Mutale, Kenny Situtu, Gershom Chongwe and 32 more

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

42 authors.

Christine ProsperiDepartment of International Health, International Vaccine Access Center, Johns Hopkins University, Baltimore, Maryland, United States of America.
Natalya KostandovaDepartment of International Health, International Vaccine Access Center, Johns Hopkins University, Baltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0002-6184-531X
Andrea C CarcelenDepartment of International Health, International Vaccine Access Center, Johns Hopkins University, Baltimore, Maryland, United States of America.
Kalumbu H MatakalaMacha Research Trust, Macha, Zambia.ORCID https://orcid.org/0000-0003-3536-2645
Innocent C BwalyaNational Health Research and Training Institute, Ndola, Zambia.
Gloria MusukwaMacha Research Trust, Macha, Zambia.
Mutinta HamahuwaMacha Research Trust, Macha, Zambia.
Irene MutaleNational Health Research and Training Institute, Ndola, Zambia.
Kenny SitutuNational Health Research and Training Institute, Ndola, Zambia.
Gershom ChongweNational Health Research and Training Institute, Ndola, Zambia.ORCID https://orcid.org/0000-0003-3303-308X
Phillimon NdubaniMacha Research Trust, Macha, Zambia.
Edgar SimulunduMacha Research Trust, Macha, Zambia.
George ChipuluChoma General Hospital, Choma, Zambia.
Joseph MusowoyaNdola Teaching Hospital, Ndola, Zambia.
Jonathan Kaunda MwansaArthur Davison Children's Hospital, Ndola, Zambia.
Vickins MalamboChoma General Hospital, Choma, Zambia.
Moses ChakopoArthur Davison Children's Hospital, Ndola, Zambia.
Chaambwa HachooseChoma General Hospital, Choma, Zambia.
Miriam KabaloArthur Davison Children's Hospital, Ndola, Zambia.
Emmanuel LuwayaArthur Davison Children's Hospital, Ndola, Zambia.ORCID https://orcid.org/0000-0001-9518-2422
Auto MadzireChoma General Hospital, Choma, Zambia.
Rebecca MoyoNdola Teaching Hospital, Ndola, Zambia.
Clement Chimuka MukwengoChoma General Hospital, Choma, Zambia.
Tula C MwansaNdola Teaching Hospital, Ndola, Zambia.
Sandwe NkomaArthur Davison Children's Hospital, Ndola, Zambia.
Brian SiwakwiNdola Teaching Hospital, Ndola, Zambia.
Chipo SyamunguluArthur Davison Children's Hospital, Ndola, Zambia.
Susan NafukweChoma General Hospital, Choma, Zambia.
Evans BethaNational Health Research and Training Institute, Ndola, Zambia.
Lombe KampambaNational Health Research and Training Institute, Ndola, Zambia.
Kelvin KapunguNational Health Research and Training Institute, Ndola, Zambia.
Japhet MatobaMacha Research Trust, Macha, Zambia.
Passwell MunachoongaMacha Research Trust, Macha, Zambia.
Mathias MulekaMacha Research Trust, Macha, Zambia.
Webster MufwambiNational Health Research and Training Institute, Ndola, Zambia.
Sydney VwalikaMacha Research Trust, Macha, Zambia.
Alvira Z HasanDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public HealthBaltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0001-5665-2372
Amy K WinterDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public HealthBaltimore, Maryland, United States of America.
Constance SakalaMinistry of Health, Government of the Republic of ZambiaLusaka, Zambia.
Francis Dien MwansaMinistry of Health, Government of the Republic of ZambiaLusaka, Zambia.
William J MossDepartment of International Health, International Vaccine Access Center, Johns Hopkins University, Baltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0001-6579-3513
Simon MutemboDepartment of International Health, International Vaccine Access Center, Johns Hopkins University, Baltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0002-5389-5966

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Residual blood specimens collected at health care facilities provide a low-cost and readily available specimen source to monitor population immunity through serological surveillance compared to more resource-intensive probability-based surveys. Despite concerns about the representativeness of these specimens, there has recently been increased interest in the use of residual specimens, driven by the need for rapid estimates of seroprevalence during outbreaks to inform response and prevention. Although residual specimen collection is a key component of surveillance systems in some settings, there is limited evidence of its implementation in low- and middle-income countries. We conducted a pilot project at three health facilities in two districts in Zambia between September 2021 through July 2022 to demonstrate the feasibility of residual blood specimen collection integrated into the health system to estimate measles seroprevalence. Through this pilot project, we were able to collect residual pediatric and adult specimens but with some modifications needed if residual specimen collection were to be implemented at scale, such as better integration into the routine functioning of laboratories and health facilities. This paper summarizes our experiences designing and implementing this residual blood specimen collection, including the lessons learned and recommendations for collecting residual specimens from hospitals.

Indexed as

Hospitals, DistrictMeaslesFeasibility StudiesHumansPilot ProjectsSeroepidemiologic StudiesZambia

Identifiers

PMID42550844
PMCPMC13436745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.